Switch theme
Sign up to access all valuation multiples
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 60% of revenue and 70% of operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly across more than 100 countries. In fiscal 2022, Ansell earned 45% of revenue in North America, 33% from Europe, Middle East and Africa, 14% across Asia-Pacific and the remaining 8% in Latin America.
1920
16.0K+
LTM Revenue $3.2B
LTM EBITDA $526M
$3.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ansell has a last 12-month revenue (LTM) of $3.2B and a last 12-month EBITDA of $526M.
In the most recent fiscal year, Ansell achieved revenue of $1.0B and an EBITDA of $131M.
Ansell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ansell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $404M | XXX | XXX | XXX |
| Gross Margin | 43% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $526M | XXX | $131M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $435M | XXX | $36.7M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $278M | XXX | $49.5M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 27, 2025, Ansell's stock price is AUD 30 (or $20).
Ansell has current market cap of AUD 4.4B (or $2.9B), and EV of AUD 5.3B (or $3.4B).
See Ansell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4B | $2.9B | XXX | XXX | XXX | XXX | $1.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 27, 2025, Ansell has market cap of $2.9B and EV of $3.4B.
Ansell's trades at 2.2x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Ansell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ansell has a P/E ratio of 15.9x.
See valuation multiples for Ansell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 12.2x | XXX | 21.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.9x | XXX | 25.0x | XXX | XXX | XXX |
| EV/FCF | 17.7x | XXX | 20.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnsell's last 12 month revenue growth is 7%
Ansell's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $23K for the same period.
Ansell's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ansell's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ansell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 50% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $23K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma Trading | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ansell acquired XXX companies to date.
Last acquisition by Ansell was XXXXXXXX, XXXXX XXXXX XXXXXX . Ansell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ansell founded? | Ansell was founded in 1920. |
| Where is Ansell headquartered? | Ansell is headquartered in Australia. |
| How many employees does Ansell have? | As of today, Ansell has 16.0K+ employees. |
| Who is the CEO of Ansell? | Ansell's CEO is Mr. Neil I. Salmon. |
| Is Ansell publicy listed? | Yes, Ansell is a public company listed on ASX. |
| What is the stock symbol of Ansell? | Ansell trades under ANN ticker. |
| When did Ansell go public? | Ansell went public in 1985. |
| Who are competitors of Ansell? | Similar companies to Ansell include e.g. Polymed, Farmaceutica Remedia, Etropal, Sopharma. |
| What is the current market cap of Ansell? | Ansell's current market cap is $2.9B |
| What is the current revenue of Ansell? | Ansell's last 12 months revenue is $3.2B. |
| What is the current revenue growth of Ansell? | Ansell revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Ansell? | Current revenue multiple of Ansell is 1.7x. |
| Is Ansell profitable? | Yes, Ansell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ansell? | Ansell's last 12 months EBITDA is $526M. |
| What is Ansell's EBITDA margin? | Ansell's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Ansell? | Current EBITDA multiple of Ansell is 10.0x. |
| What is the current FCF of Ansell? | Ansell's last 12 months FCF is $299M. |
| What is Ansell's FCF margin? | Ansell's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Ansell? | Current FCF multiple of Ansell is 17.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
